Prothena Corp. Plc
(NASDAQ : PRTA)

( )
PRTA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -1.20%136.260.0%$876.09m
AMGNAmgen, Inc. 0.19%243.871.5%$800.58m
GILDGilead Sciences, Inc. -0.21%62.241.0%$521.82m
VRTXVertex Pharmaceuticals, Inc. 3.02%254.171.9%$450.04m
REGNRegeneron Pharmaceuticals, Inc. 1.47%655.012.6%$404.30m
ILMNIllumina, Inc. 0.08%233.743.3%$282.61m
NVAXNovavax, Inc. -7.50%48.0075.7%$279.78m
BIIBBiogen, Inc. -0.37%198.381.8%$245.45m
BNTXBioNTech SE -4.81%151.200.0%$211.21m
SNSSSunesis Pharmaceuticals, Inc. 13.90%2.130.7%$148.89m
EXASEXACT Sciences Corp. -3.33%50.5517.7%$132.03m
NKTXNkarta, Inc. -1.14%13.860.0%$111.92m
TECHBio-Techne Corp. -1.53%362.134.5%$98.39m
BMRNBioMarin Pharmaceutical, Inc. -0.53%77.324.2%$97.55m
TXG10X Genomics, Inc. -2.79%46.300.0%$89.30m

Company Profile

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.